GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mainz Biomed NV (NAS:MYNZ) » Definitions » Debt-to-Asset

Mainz Biomed NV (Mainz Biomed NV) Debt-to-Asset : 0.48 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Mainz Biomed NV Debt-to-Asset?

Mainz Biomed NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.23 Mil. Mainz Biomed NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.20 Mil. Mainz Biomed NV's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $15.41 Mil. Mainz Biomed NV's debt to asset for the quarter that ended in Dec. 2023 was 0.48.


Mainz Biomed NV Debt-to-Asset Historical Data

The historical data trend for Mainz Biomed NV's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mainz Biomed NV Debt-to-Asset Chart

Mainz Biomed NV Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
3.37 4.43 0.26 0.16 0.48

Mainz Biomed NV Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.19 0.44 0.57 0.48

Competitive Comparison of Mainz Biomed NV's Debt-to-Asset

For the Diagnostics & Research subindustry, Mainz Biomed NV's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mainz Biomed NV's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Mainz Biomed NV's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Mainz Biomed NV's Debt-to-Asset falls into.



Mainz Biomed NV Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Mainz Biomed NV's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Mainz Biomed NV's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mainz Biomed NV  (NAS:MYNZ) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Mainz Biomed NV Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Mainz Biomed NV's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Mainz Biomed NV (Mainz Biomed NV) Business Description

Traded in Other Exchanges
Address
Robert Koch Strasse 5, Sirius Gutenberg Park, Mainz, RP, DEU, 55129
Mainz Biomed NV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. Its main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results.